{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13399"}, {"@name": "filename", "#text": "19364_puttini_io_me_araca.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "IGOR DE OLIVEIRA PUTTINI \n\n \n\n \n\n \n\n \n\n \n\n \n\nAN\u00c1LISE HISTOL\u00d3GICA, \n\nIMUNOISTOQU\u00cdMICA E POR MICRO-CT \n\nDO PROCESSO DE REPARO \n\nALVEOLAR DE RATOS \n\nORQUIECTOMIZADOS SUBMETIDOS \u00c0 \n\nTERAPIA COM TERIPARATIDA \n\n \n\n \n\n \n\n \n\n \n\nAra\u00e7atuba \u2013 S\u00e3o Paulo \n\n2017\n\n\n\n \n\n \n\nIGOR DE OLIVEIRA PUTTINI \n\n \n\n \n\nAN\u00c1LISE HISTOL\u00d3GICA, \n\nIMUNOISTOQU\u00cdMICA E POR MICRO-CT \n\nDO PROCESSO DE REPARO \n\nALVEOLAR DE RATOS \n\nORQUIECTOMIZADOS SUBMETIDOS \u00c0 \n\nTERAPIA COM TERIPARATIDA \n\nDisserta\u00e7\u00e3o apresentada \u00e0 Faculdade de \nOdontologia do Campus de Ara\u00e7atuba \u2013 \nUniversidade Estadual Paulista \u201cJ\u00falio de \nMesquita Filho\u201d- UNESP, para obten\u00e7\u00e3o do \nT\u00edtulo de MESTRE EM ODONTOLOGIA \n(\u00c1rea de concentra\u00e7\u00e3o em Cirurgia e \nTraumatologia Bucomaxilofacial). \n\n \n\n \n\n \n\nOrientador: Prof\na\n. Adj. Roberta Okamoto \n\nCoorientadora: Prof\u00aa. Adj. Mariza Akemi Matsumoto \n\n \n\nAra\u00e7atuba \u2013 S\u00e3o Paulo \n\n2017\n\n\n\n \n\n \n\n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nCataloga\u00e7\u00e3o na Publica\u00e7\u00e3o (CIP) \n\nDiretoria T\u00e9cnica de Biblioteca e Documenta\u00e7\u00e3o \u2013 FOA / UNESP \n\n \n\n Puttini, Igor de Oliveira. \n\nP993a  An\u00e1lise histol\u00f3gica, imunoistoqu\u00edmica e por micro-ct do \n\nprocesso de reparo alveolar de ratos orquiectomizados submetidos \u00e0 \n\nterapia com teriparatida / Igor de Oliveira Puttini. - Ara\u00e7atuba, \n\n 2017 \n\n  71 f. : il. ; tab. \n\n \n\n  Disserta\u00e7\u00e3o (Mestrado) \u2013 Universidade Estadual Paulista, \n\n Faculdade de Odontologia de Ara\u00e7atuba \n\n  Orientadora: Profa. Roberta Okamoto \n  Coorientadora: Profa. Mariza Akemi Matsumoto \n \n\n  1. Osso e ossos 2. Teriparatida 3. Homens 4. Osteoporose \n\n  I. T. \n\n    Black D7 \n\n    CDD 617.6 \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDEDICAT\u00d3RIA   \n\n\n\n \n\n \n\n \n\nDedicat\u00f3ria \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAos meus Pais Geraldo Gilson Puttini e Lucy Imaculada de \n\nOliveira Puttini \n\nPelo suporte, doa\u00e7\u00e3o e sacrif\u00edcios. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAGRADECIMENTOS   \n\n\n\n \n\n \n\nAgradecimentos \n\nMeu sincero agradecimento a todos que foram respons\u00e1veis por fazer \n\ndeste trabalho hoje uma realidade. \n\n\u00c0 minha Orientadora Professora Roberta Okamoto pela dedica\u00e7\u00e3o, \n\nhumanidade e profundo conhecimento compartilhado, \n\nA minha Co-orientadora Professora Marisa Akemi Matsumoto pela \n\noportunidade e dedic\u00e7\u00e3o,  \n\nAo Professor Leonardo Perez Faverani que al\u00e9m da ci\u00eancia ensina como \n\nser humano, \n\nA todos os funcion\u00e1rios que permitiram, atrav\u00e9s de seus esfor\u00e7os di\u00e1rios, \n\nque hoje este trabalho e toda a minha gradua\u00e7\u00e3o tenham sido conclu\u00eddos com \u00eaxito \n\ne sucesso, \n\n\u00c0 Universidade Estadual Paulista \u201cJ\u00falio de Mesquita Filho\u201d \u2013 \n\nFaculdade de Odontologia de Ara\u00e7atuba por ter me recebido e oferecido todos \n\nos recursos e estrutura para a minha p\u00f3s-gradua\u00e7\u00e3o, \n\nA CAPES pelo aux\u00edlio durante todo o per\u00edodo, \n\nMeus sinceros agradecimentos aos amigos da p\u00f3s-gradua\u00e7\u00e3o Valthierre \n\nNunes, Jo\u00e3o Paulo Bonardi, Pedro Henrique, Leonardo Freitas, Erick Neiva, \n\nF\u00e1bio Batista, Gabriel Mulinari, Andr\u00e9 Oliva, Ciro Duailibe, Rodrigo Pereira e \n\nWilliam Ricardo, pelos momentos compartilhados, ajudas e conselhos, sem voc\u00eas \n\no dif\u00edcil talvez se tornasse imposs\u00edvel, \n\nAos meus amigos Tarik Polo, Juliana Zorzi, Andr\u00e9 Fabris, Sabrina \n\nFerreira, Gustavo Momesso, Gestter Willian Lattari Tessarin, Paulo Roberto \n\n\n\n \n\n \n\nPompeu Gallo, Cesar Diogo, Vitor Scalet, Jo\u00e3o Vitor e \u00c9verton Ribeiro Lelis \n\npor terem compartilhado grande parte de minha vida e oferecido uma amizade real, \n\n\u00c0s Minhas av\u00f3s Sebastiana Ferreira de Oliveira e Hilda Alsleben Puttini \n\ne ao meu finado av\u00f4 Elias da Silva de Oliveira por todo o amor que sempre \n\nrecebi, \n\nAo meu irm\u00e3o Enzo de Oliveira Puttini por ser essa pessoa pura que \n\nserve de inspira\u00e7\u00e3o, \n\nAos meus Pais Geraldo Gilson Puttini e Lucy Imaculada de Oliveira \n\nPuttini que com palavras n\u00e3o poderia agradecer o que fizeram por mim \n\nE por fim a Deus, por ter sido sempre bom e fiel. \n\nObrigado!  \n\n\n\n \n\n \n\nEp\u00edgrafe \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\u201cUma pessoa que nunca cometeu um erro nunca tentou nada de novo.\u201d  \n \n \n\nAlbert Einstein \n  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nLISTAS E SUM\u00c1RIO  \n\n\n\n \n\n \n\nLista de Figuras \n\nFigura 1 \u2013 Linha do tempo experimental                                                                 45 \n \n\nFigura 2 \u2013 A: Antissepsia com PVPI em ambos os sacos escrotais; B: Incis\u00e3o; C e \n\nD: Exposi\u00e7\u00e3o de ambos escrotos; E: Laqueamento do ducto deferente e do \n\nped\u00edculo vascular; F: Remo\u00e7\u00e3o de ambos escrotos com auxilio de uma tesoura; G: \n\nSutura; H: Ambos escrotos removidos (Orquiectomia).                                           45 \n\nFigura 3 \u2013 1: Antissepsia com PVPI na \u00e1rea cirurgica; 2: Luxa\u00e7\u00e3o do dente com \n\nalavanca 3: Luxa\u00e7\u00e3o do elemento dental com f\u00f3rceps adaptado; 4: exodontia.     46 \n\nFigura 4 \u2013 Imagem em 3 dimens\u00f5es obtida atrav\u00e9s do software DataViewer da \n\nmicro-ct.                                                                                                                    46 \n\nFigura 5 \u2013 Sele\u00e7\u00e3o da \u00e1rea de interesse da an\u00e1lise de micro-ct atrav\u00e9s do software \n\nCT Analyzer.                                                                                                             47 \n\nFigura 6 \u2013 Utiliza\u00e7\u00e3o da ferramenta thershould para mensura\u00e7\u00f5es da micro-ct \n\natrav\u00e9s de escalas de cinza feita pelo software CT Analyzer.                                 47 \n\nFigura 7 \u2013 Quantifica\u00e7\u00e3o do volume \u00f3sseo. Volume equiparados. Teste de Shapiro-\n\nWilk e p\u00f3s-teste de Tukey.                                                                                       48 \n\nFigura 8 \u2013 Quantifica\u00e7\u00e3o do percentual de volume \u00f3sseo. Percentuais aproximados \n\nTeste de Shapiro-Wilk e p\u00f3s-teste de Tukey.                                                          48 \n\nFigura 9 \u2013 Quantifica\u00e7\u00e3o da espessura trabecular. Valores similares do SHAM e \n\nORQTRAT Teste de Shapiro-Wilk e p\u00f3s-teste de Tukey. (p>0,05).                        49 \n\n\n\n \n\n \n\nFigura 10 \u2013 Quantifica\u00e7\u00e3o da separa\u00e7\u00e3o entre as trab\u00e9culas. Valores maiores para \n\nSHAM e ORQTRAT e menor para o grupo ORQ. Teste de Shapiro-Wilk e p\u00f3s-teste \n\nde Tukey.                                                                                                                  49 \n\nFigura 11 \u2013 Quantifica\u00e7\u00e3o do n\u00famero de trab\u00e9culas. Valor maior para ORQ e \n\nmenor para SHAM e ORQTRAT. Teste de Shapiro-Wilk e p\u00f3s-teste de Tukey. \n\n(p>0,05).                                                                                                                   50 \n\nFigura 12 \u2013 Quantifica\u00e7\u00e3o do percentual de porosidade total. Valor compat\u00edvel com \n\nosso mais poroso para o grupo ORQ e menos poroso para SHAM e ORQTRAT \n\n(p>0,05).                                                                                                                   50 \n\nFigura 13 \u2013 Prancha com as imagens histol\u00f3gicas e imunohistoqu\u00edmicas dos \n\nalv\u00e9olos em repara\u00e7\u00e3o no per\u00edodo de 42 dias ap\u00f3s a exodontia em aumento de \n\n40x.                                                                                                                           52 \n\n  \n\n\n\n \n\n \n\nLista de Tabelas \n\nTabela 1 \u2013 Grupos experimentais de acordo com o tratamento com Teripatida     44 \n\n \n \n\n  \n\n\n\n \n\n \n\nLista de Abreviaturas \n\n \nPTH - Paratorm\u00f4nio  \n\nMicro CT - Microtomografia Computadorizada \n\nHE \u2013 Hematoxilina e Eosina \n\nBMD \u2013 Densidade mineral \u00f3ssea \n\nBV - Volume \u00f3sseo \n\nBV/TV - Percentual de volume \u00f3sseo \n\nTb.Th - Espessura trabecular \n\nTb.N - N\u00famero de trab\u00e9culas \n\nTb.Th \u2013 Espessura das trabeculas \n\nTb.Sp - Separa\u00e7\u00e3o entre as trab\u00e9culas \n\nPo-tot - Percentual de porosidade total \n\nn\no\n - N\u00famero \n\ng - Grama \n\nmm - Mil\u00edmetro  \n\n\u00b5g/kg/dia - Micrograma por quilograma por dia \n\nml - Mililitro \n\nKv - Quilovolt  \n\n?m - Micrometro \n\nmm\n3\n -  Mil\u00edmetros c\u00fabicos \n\n \n\n \n\n \n\n  \n\n\n\n \n\n \n\nSum\u00e1rio \n\n1. An\u00e1lise histol\u00f3gica, imunoistoqu\u00edmica e por micro-ct do processo de \n\nreparo alveolar de ratos orquiectomizados submetidos \u00e0 terapia com \n\nteriparatida                                                                                                            16 \n\n1.1 Resumo                               17 \n\n1.2 Abstract                               19 \n\n1.3 Introdu\u00e7\u00e3o                              21 \n\n1.4 Materiais e m\u00e9todos                             24 \n\n1.5 Resultados                              30 \n\n1.6 Discuss\u00e3o                     33 \n\n1.7 Refer\u00eancias                                                                37 \n\n1.8 Lista de tabelas                                                                                               44 \n\n1.9 Lista de figuras                                                                                               45 \n\n2.0 Anexo A - Comit\u00ea de \u00e9tica                                       54 \n\n2.1 Anexo B - Normas para publica\u00e7\u00e3o (COIR)                                                  55 \n\n \n\n\n\n16 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAN\u00c1LISE HISTOL\u00d3GICA, IMUNOISTOQU\u00cdMICA E \n\nPOR MICRO-CT DO PROCESSO DE REPARO \n\nALVEOLAR DE RATOS ORQUIECTOMIZADOS \n\nSUBMETIDOS \u00c0 TERAPIA COM TERIPARATIDA \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n*Este trabalho foi formatado de acordo com as normas do peri\u00f3dico Clinical Oral \n\nImplants Research \n\n\n\n17 \n\n \n\nPuttini, I.O. AN\u00c1LISE HISTOL\u00d3GICA, IMUNOISTOQU\u00cdMICA E POR MICRO-\n\nCT DO PROCESSO DE REPARO ALVEOLAR DE RATOS \n\nORQUIECTOMIZADOS SUBMETIDOS \u00c0 TERAPIA COM TERIPARATIDA. \n\n2014. Trabalho de Conclus\u00e3o de Conclus\u00e3o de Curso \u2013 Faculdade de \n\nOdontologia, Universidade Estadual Paulista, Ara\u00e7atuba, 2014. \n\n \n\nResumo \n\n \n\nObjetivos: Avaliar a influ\u00eancia da teriparatida, administrada sistemicamente, \n\nnas caracter\u00edsticas morfol\u00f3gicas e estruturais do osso reparacional formado \n\ndurante o processo de reparo alveolar em ratos com osteoporose induzida \n\n(orquiectomizados). \n\nMateriais e M\u00e9todos: Foram utilizados 48 ratos divididos 3 em grupos \n\ndiscriminados a seguir: 16 ratos orquiectomizados tratados com teriparatida,  \n\n16 ratos orquiectomizados sem tratamento e  16 ratos sham. Deste modo, \n\ndividindo-se 8 ratos para an\u00e1lise histol\u00f3gica e para a an\u00e1lise imuno-\n\nhistoqu\u00edmica que foi feita atrav\u00e9s da express\u00e3o das prote\u00ednas TRAP, \n\nosteocalc\u00edna, e WNT, com per\u00edodo de eutan\u00e1sia em 42 dias (tecidos \n\ndescalcificados), e 8 ratos para an\u00e1lise microtomogr\u00e1fica (tecidos calcificados), \n\nnesta an\u00e1lise o per\u00edodo de eutan\u00e1sia foi de 60 dias p\u00f3s exod\u00f4ntico. Os dados \n\nquantitativos foram submetidos ao teste de normalidade e este indicou um \n\nteste estat\u00edstico mais adequado (param\u00e9trico VS n\u00e3o param\u00e9trico). Foi adotado \n\npara todos os testes n\u00edvel de signific\u00e2ncia de 5%. \n\n\n\n18 \n\n \n\nResultados: A an\u00e1lise histol\u00f3gica mostrou melhores padr\u00f5es de neoforma\u00e7\u00e3o \n\n\u00f3ssea para o grupo ORQTRAT com maior quantidade de tecido mineralizado e \n\npouco tecido conjuntivo. Os resultados imunohistoqu\u00edmicos novamente \n\nmostraram um padr\u00e3o de reparo melhor no grupo ORQTRAT com \n\nmarca\u00e7\u00f5es mais intensas de wnt e osteocalc\u00edna e marca\u00e7\u00f5es mais fracas de \n\ntrap. Aos resultados da microtomografia novamente o grupo ORQTRAT se \n\ndemostrou melhor que os demais, com maior volume \u00f3sseo (BV), porcentagem \n\nde trabeculado \u00f3sseo (BV/TV), espessura do trabeculado \u00f3sseo (Tb.Th) e \n\nsepara\u00e7\u00e3o entre as trab\u00e9culas (Tb.Sp). E, menor n\u00famero (Tb.N) e menor \n\nporosidade total \u00f3ssea (Po.Tot) quando comparado ao grupo sem tratamento. \n\nConclus\u00f5es: Foi poss\u00edvel concluir que o tratamento com Teriparatida melhorou \n\npar\u00e2metros importantes que determinam a qualidade do tecido \u00f3sseo \n\nreparacional mesmo na presen\u00e7a da condi\u00e7\u00e3o sist\u00eamica estabelecida nos \n\nanimais. \n\nPalavras-chave: Osso e ossos, Teriparatida, Homens, Osteoporose. \n\n  \n\n\n\n19 \n\n \n\nPutini, I.O. Orchiectomized rats submitted to teriparatide therapy. \n\nHistological, Immunohistochemical and micro-ct analysis of the alveolar \n\nrepair process. 2014. Trabalho de Conclus\u00e3o de Conclus\u00e3o de Curso \u2013 \n\nFaculdade de Odontologia, Universidade Estadual Paulista, Ara\u00e7atuba, 2014. \n\n \n\nAbstract \n\n \n\nObjectives: To evaluate the influence of teriparatide, systemically \n\nadministered, on the morphological and structural characteristics of the \n\nreparative bone formed during the alveolar repair process in rats with induced \n\nosteoporosis (orchiectomized). \n\nMaterials and Methods: Forty-eight rats were divided into three groups: 16 \n\norchiectomized rats treated with teriparatide, 16 unqualified orchiectomized rats \n\nand 16 sham rats. Thus, 8 rats were divided for histological analysis and for \n\nImmunohistochemical analysis, which was done by the expression of TRAP \n\nproteins, osteocalcin, and WNT, with euthanasia at 42 days (decalcified \n\ntissues), and 8 rats for analysis for microtomographic analysis (calcified \n\ntissues). In this analysis, the euthanasia period was at 60 days after the \n\nextraction surgery. The quantitative data were submitted to the normality test \n\nand this indicated the most adequate statistical test (parametric vs non-\n\nparametric). The significance level of 5% was adopted for all tests. \n\nResults:  Histological analysis showed better patterns of bone neoformation for \n\nthe ORQTRAT group with greater amount of mineralized tissue and little \n\nconnective tissue. The immunohistochemical results again showed a better \n\n\n\n20 \n\n \n\nrepair pattern in the ORQTRAT group with more intense markings of wnt and \n\nosteocalcin and weaker trap markings. To the results of the microtomography \n\nagain the ORQTRAT group showed better than the others, with higher bone \n\nvolume (BV), percentage of trabecular bone (BV / TV), thickness of trabecular \n\nbone (Tb.Th) and separation between trabeculae (Tb.Sp). And, lower number \n\n(Tb.N) and lower total bone porosity (Po.Tot) when compared to the non-treated \n\ngroup. \n\nConclusions: It was possible to conclude that the treatment with Teriparatide \n\nimproved important parameters that determine the quality of reparative bone \n\ntissue even in the presence of the established systemic condition in the \n\nanimals. \n\nKey-words: Bone and Bone, Teriparatide, Men, Osteoporosis. \n\n  \n\n\n\n21 \n\n \n\n1.3 Introdu\u00e7\u00e3o  \n\n  \n\nAinda que a maioria das pesquisas de osteoporose no passado tenha \n\nseu foco em mulheres, a osteoporose est\u00e1 se tornando um problema relevante \n\nnos homens. Um em cada oito homens acima dos 50 anos ter\u00e3o uma fratura \n\nrelacionada \u00e0 osteoporose (Cooper; Melton III, 1992). E este quadro tem \n\nperspectiva de aumentar com o envelhecimento da popula\u00e7\u00e3o masculina \n\n(Burge; Dawson-Hughes; Solomon; et al, 2007). A osteoporose no g\u00eanero \n\nmasculino pode ser classificada como prim\u00e1ria ou secund\u00e1ria, na prim\u00e1ria ela \n\nainda pode ser dividia em idiop\u00e1tica e relacionada \u00e0 idade baseado na idade do \n\ndiagn\u00f3stico. \n\nA osteoporose prim\u00e1ria compromete aproximadamente cinquenta por \n\ncento dos casos em homens e \u00e9 uma condi\u00e7\u00e3o heterog\u00eanea multifatorial em \n\nrela\u00e7\u00e3o ao desenvolvimento da osteoporose quando nenhuma causa \n\nsecund\u00e1ria \u00e9 identificada (Khosla; Amin; Orwoll, 2008). Perda \u00f3ssea \n\nrelacionada \u00e0 idade acontece em homens acima dos 70 anos, combinado a \n\ndieta e n\u00edveis hormonais deficientes (Khosla; Amin; Orwoll, 2008). Ao contr\u00e1rio \n\ndo que acontece com as mulheres p\u00f3s-menopausa, a redu\u00e7\u00e3o da neoforma\u00e7\u00e3o \n\n\u00f3ssea \u00e9 o mecanismo predominante da perda \u00f3ssea relacionada \u00e0 idade nos \n\nhomens, tornando os agentes anab\u00f3licos uma op\u00e7\u00e3o de tratamento l\u00f3gica para \n\nhomens com osteoporose (Gagnon; Li; Ebeling, 2008). Ambos a queda de \n\nabsor\u00e7\u00e3o de c\u00e1lcio no intestino e alta preval\u00eancia de insufici\u00eancia de vitamina D \n\nem homens idosos contribuem para o elevado n\u00edvel s\u00e9rico de horm\u00f4nio da \n\nparatireoide (PTH) e perda \u00f3ssea (Lips, 2001) Outros mecanismos potenciais \n\npelos quais os suficientes n\u00edveis de vitamina D podem preservar a sa\u00fade dos \n\n\n\n22 \n\n \n\nossos \u00e9 a indu\u00e7\u00e3o de osteoblastog\u00eanese e atividade osteobl\u00e1stica, a ativa\u00e7\u00e3o \n\nde genes osteog\u00eanicos, preven\u00e7\u00e3o da apoptose de osteoblastos e de inibi\u00e7\u00e3o \n\nde adipog\u00eanese (Duque; Abadaimi; Henderson; et al, 2004; Duque; Macoritto; \n\nDion; et al, 2005). \n\nMuitos outros fatores hormonais tamb\u00e9m foram incriminados na \n\nfisiopatologia da perda \u00f3ssea relacionada com a idade nos homens. Ambos os \n\nn\u00edveis livre ou biodispon\u00edvel de testosterona e estradiol diminuem com a idade, \n\ndevido ao aumento do n\u00edvel s\u00e9rico da globulina ligadora de horm\u00f4nios sexuais \n\n(SHBG) e falha de compensa\u00e7\u00e3o do eixo hipot\u00e1lamo/hip\u00f3fise/test\u00edculo (Orwoll; \n\nLambert; Marshall; et al, 2006). Embora v\u00e1rias evid\u00eancias suportem um papel \n\ndominante de estrog\u00eanio na manuten\u00e7\u00e3o da massa \u00f3ssea em homens, a \n\ntestosterona tamb\u00e9m contribui (Falahati-Nini; Riggs; Atkinson; et al, 2000; \n\nLeder; LeBlanc; Schoenfeld; et al, 2003; Amin; Zang; Felson; et al, 2006). Os \n\nf\u00e1rmacos ainda n\u00e3o foram estudados em homens com osteoporose da mesma \n\nforma que foram em mulheres, e apenas alguns tratamentos foram aprovados \n\npara o uso em homens. Destes se incluem os bisfosfonatos e teriparatida \n\n(Gagnon; Li; Ebeling, 2008). \n\nA terapia com bisfosfonatos tem se mostrado efetiva em aumentar a \n\ndensidade mineral \u00f3ssea (BMD) em homens com osteoporose prim\u00e1ria, assim \n\ncomo em homens com osteoporose secund\u00e1ria, incluindo por hipogonadismo \n\n(Orwoll; Ettinger; Weiss; et al, 2000; Ringe; Faber; Farahmand; et al, 2006). \n\nEmbora a maioria dos ensaios de bisfosfonatos orais nos homens tenham sido \n\nde fraca pot\u00eancia ou n\u00e3o principalmente destinado a avaliar o seu efeito sobre \n\na incid\u00eancia de fraturas, alguns estudos mostraram uma redu\u00e7\u00e3o significativa \n\n\n\n23 \n\n \n\nna ocorr\u00eancia de novas fraturas vertebrais (Orwoll; Ettinger; Weiss; et al, 2000; \n\nRinge; Faber; Farahmand; et al, 2006). Mesmo que o aumento da densidade \n\nmineral \u00f3ssea com a terapia com bisfosfonatos seja semelhante em homens e \n\nmulheres (Ho; Frauman; Thomson; et al, 2000) e poderia, portanto, \n\nteoricamente, se traduzir em uma redu\u00e7\u00e3o do risco de fratura semelhante ao \n\nobservado em mulheres, mais dados s\u00e3o necess\u00e1rios para determinar os \n\nbenef\u00edcios de bisfosfonatos orais em homens. Os bisfosfonatos s\u00e3o geralmente \n\nbem tolerados. No entanto, tanto bisfosfonatos intravenosos e orais t\u00eam sido \n\nassociados em casos de osteonecrose da mand\u00edbula, embora uma quantidade \n\nlimitada de dados sugira que n\u00e3o h\u00e1 um claro aumento do risco desta \n\ncomplica\u00e7\u00e3o em pacientes com osteoporose (Bilezikian, 2006). \n\nEm diversos casos de osteoporose, colocar um fim na perda \u00f3ssea pode \n\nn\u00e3o ser suficiente. Nestes casos, tratamentos que estimulam a neoforma\u00e7\u00e3o \n\n\u00f3ssea e reverta a deteriora\u00e7\u00e3o \u00f3ssea podem se tornar uma op\u00e7\u00e3o de \n\ntratamento vi\u00e1vel (National Cancer Institute - EUA - 2001). Em homens, em que \n\na deficiente forma\u00e7\u00e3o \u00f3ssea se da como importante fator etiol\u00f3gico, um \n\ntratamento anab\u00f3lico se da como uma abordagem l\u00f3gica. A teriparatida \u00e9 o \n\n\u00fanico agente anab\u00f3lico atualmente aprovado para o tratamento da osteoporose \n\nem homens (Cheng; Gupta, 2012). \n\nO processo de reparo alveolar \u00e9 um interessante modelo para estudar a \n\ndin\u00e2mica do tecido \u00f3sseo, pois representa uma situa\u00e7\u00e3o na qual o organismo \n\ncria condi\u00e7\u00f5es para produ\u00e7\u00e3o de tecido \u00f3sseo com o objetivo de \n\npreenchimento total do alv\u00e9olo previamente ocupado pelo dente (Okamoto; \n\nRusso, 1973; Carvalho; Okamoto, 1987). Uma quest\u00e3o importante consiste em \n\n\n\n24 \n\n \n\nobter mais respostas sobre como produzir um tecido mineralizado de boa \n\nqualidade (Von Wowern; Kollerup, 1992; Elsubeihi; Heersch, 2002). \n\nConsiderando o aumento da expectativa de vida, o aumento do n\u00famero \n\nde idosos com osteoporose a procura de tratamento odontol\u00f3gico para \n\nreposi\u00e7\u00e3o de dentes perdidos, as peculiaridades do processo de reparo \n\nalveolar e a necessidade de obter melhores entendimentos da forma\u00e7\u00e3o do \n\ntecido \u00f3sseo no processo de reparo alveolar para que possamos obter um \n\ntecido \u00f3sseo de melhor qualidade, o presente estudo teve o objetivo de estudar \n\natrav\u00e9s de uma an\u00e1lise histom\u00e9trica o metabolismo \u00f3sseo no processo de \n\nreparo alveolar em ratos machos orquiectomizados sem tratamento \n\nfarmacol\u00f3gico, ratos orquiectomizados tratados com teriparatida e ratos Sham \n\nsem tratamento farmacol\u00f3gico para o grupo controle.  \n\n \n\n1.4 Materiais e m\u00e9todos \n\n Ap\u00f3s a aprova\u00e7\u00e3o do Comit\u00ea de \u00e9tica em pesquisa no uso de animais da \n\nFaculdade de Odontologia de Ara\u00e7atuba \u2013 UNESP (Processo FOA n\u00ba 00706-\n\n2015) (Anexo A). \n\nPara este estudo foi utilizado um total de 48 ratos (Rattus novergicus \n\nalbinus, Wistar), machos, adultos, com peso de aproximadamente 300g, os \n\nquais foram divididos em tr\u00eas grupos (n=16 por grupo) descritos a seguir: \n\nSham, representando os animais que passaram pela cirurgia f\u00edcticia apenas \n\npara simular o stress cir\u00fargico. Orq, grupo dos animais orquiectomizados para \n\ninduzir \u00e0 osteoporose, e, sem tratamento. E o \u00faltimo grupo, o Orqtrat, dos \n\nanimais tamb\u00e9m orquiectomizados, mas, tratados com teriparatida. Estes 16 \n\n\n\n25 \n\n \n\nanimais por grupo experimental foram divididos em dois subgrupos de an\u00e1lises, \n\n8 para o subgrupo dos tecidos desclac\u00edficados que analisou por via de \n\nhistologia em H&amp;E e imunohistoqu\u00edmica, com periodo de eutan\u00e1sia dos 8 \n\nanimais em 42 dias. E ainda 8 ratos para o subgrupo dos tecidos calcificados, \n\nonde foi realizado an\u00e1lise pela micro-ct, com per\u00edodo de eutan\u00e1sia de 60 dias \n\n(Figura 1). Estes animais foram mantidos em gaiolas, e alimentados com ra\u00e7\u00e3o \n\nbalanceada (NUVILAB, Curitiba PR, Brasil) contendo 1.4% Ca e 0.8% P e \u00e1gua \n\nad libitum.  \n\n \n\nORQUIECTOMIA \n\nOs ratos dos grupos orquiectomizados e orquiectomizados tratados com \n\nteriparatida foram anestesiados com cloridrato de xilazina (Xilazina - Coopers, \n\nBrasil, Ltda.) e Cloridrato de Cetamina (Cloridrato de quetamina injet\u00e1vel, Fort \n\nDodge, Sa\u00fade Animal Ltda.) e, a seguir, foram imobilizados sobre prancha \n\ncir\u00fargica em posi\u00e7\u00e3o de dec\u00fabito dorsal, foi realizada uma incis\u00e3o mediana \n\nanterior no escroto, abertura da t\u00fanica vaginal e exterioriza\u00e7\u00e3o dos test\u00edculos. \n\nEm seguida, os fun\u00edculos esperm\u00e1ticos foram ligados com fio de Nylon 5.0 \n\n(Ethicon \u2013 Jhonson &amp; Jhonson, New Brunswick, NJ, Estados Unidos) e \n\nseccionados. Os test\u00edculos e os epid\u00eddimos foram removidos e o escroto foi \n\nsuturado com fio de Poliglactina 910 4.0 (Vicryltm \u2013 Jhonson &amp; Jhonson, New \n\nBrunswick, NJ, Estados Unidos). Os ratos do grupo sham passaram pelo \n\nmesmo procedimento, por\u00e9m apenas foi realizada a exposi\u00e7\u00e3o cir\u00fargica dos \n\n\n\n26 \n\n \n\ntest\u00edculos e dos epid\u00eddimos sem suas respectivas remo\u00e7\u00f5es (Petroianu; Veloso; \n\nAlberti; et al, 2010). (Figura 2) \n\n \n\nTRATAMENTO COM TERIPARATIDA  \n\nLogo ap\u00f3s o procedimento cir\u00fargico os ratos foram submetidos a \n\ninje\u00e7\u00f5es subcut\u00e2nea di\u00e1rias de teriparatida numa concentra\u00e7\u00e3o de 0,5 \n\n?g/kg/dia dilu\u00eddos numa solu\u00e7\u00e3o salina est\u00e9ril a 0,1mg/ml at\u00e9 o fim dos \n\nper\u00edodos experimentais de 42 e 60 dias (Ersan; Ruijven; Bronckers, 2014). \n\n \n\nT\u00c9CNICA PARA EXTRA\u00c7\u00c3O DENTAL \n\nUm m\u00eas ap\u00f3s o in\u00edcio da terapia medicamentosa com Teriparatida os \n\nratos foram anestesiados por infiltra\u00e7\u00e3o intramuscular de Cloridrato de Xilazina \n\n0,03ml/100g de peso do animal e Cloridrato de Cetamina 0,07ml/100g de peso \n\ndo animal, foi realizada a antissepsia do campo operat\u00f3rio com \n\npolivinilpirrolidona iodada (Riodeine Ind\u00fastria Qu\u00edmica e Farmac\u00eautica Rio \n\nQu\u00edmica, S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Paulo, Brasil) e em seguida, foi realizada \n\na exodontia do incisivo superior direito, utilizando instrumental especialmente \n\nadaptado para este fim (Okamoto; Russo, 1973). A mucosa gengival foi \n\nsuturada com fio de nylon (Mononylon 4.0 \u2013 Jhonson &amp; Jhonson, New \n\nBrunswick, NJ, Estados Unidos). (Figura 3)  \n\n \n\n\n\n27 \n\n \n\n \n\nAVALIA\u00c7\u00c3O MICROTOMOGR\u00c1FICA (MICRO-CT) \n\nAp\u00f3s a fixa\u00e7\u00e3o em formol 10% tamponado por 24 horas, as maxilas \n\nforam lavadas por 48 horas em \u00e1gua corrente e armazenadas em \u00e1lcool 70%, \n\na fim de serem submetidas \u00e0 an\u00e1lise por varredura de feixe de raios-X em um \n\nsistema de microtomografia digital computadorizada (FOP/UNICAMP). As \n\npe\u00e7as foram escaneadas pelo microtom\u00f3grafo SkyScan (SkyScan 1176 Bruker \n\nMicroCT, Aatselaar, B\u00e9lgica, 2003) utilizando cortes de 9 ?m de espessura \n\n(50Kv e 500?), com filtro de Cobre e Alum\u00ednio e passo de rota\u00e7\u00e3o de 0.3 mm. \n\nAs imagens obtidas pela proje\u00e7\u00e3o dos raios-X nas amostras foram \n\narmazenadas e reconstitu\u00eddas determinando a \u00e1rea de interesse pelo software \n\nNRecon (SkyScan, 2011; Vers\u00e3o 1.6.6.0). No software Data Viewer (SkyScan, \n\nVers\u00e3o 1.4.4 64-bit) as imagens foram reconstru\u00eddas para adequa\u00e7\u00e3o do \n\nposicionamento padr\u00e3o para todas as amostras, podendo ser observada em \n\ntr\u00eas planos (transversal, longitudinal e sagital) (Figura 4). Em seguida, \n\nutilizando o software CT Analyser \u2013 CTAn (2003-11SkyScan, 2012 Bruker \n\nMicroCT Vers\u00e3o 1.12.4.0) foi definida a \u00e1rea de interesse para avalia\u00e7\u00e3o \n\ntridimensional (Figura 5). O software CTAnalyzer analisa e mede a imagem de \n\nacordo com as escalas de cinza (thershould) (Figura 6). O threshould utilizado \n\nna an\u00e1lise foi de 25-90 tons de cinza, que possibilitar\u00e1 obter o volume de osso \n\nformado nos alv\u00e9olos em repara\u00e7\u00e3o. (Ramalho-Ferreira et al., 2015) \n\n \n\n \n\n\n\n28 \n\n \n\n \n\nAN\u00c1LISE HISTOL\u00d3GICA \n\n \n\nOito animais de cada grupo experimental foram sacrificados por \n\nsobredosagem anest\u00e9sica aos 42 dias do per\u00edodo p\u00f3s-exod\u00f4ntico, foram \n\nretiradas as hemi-maxilas direitas para a realiza\u00e7\u00e3o da an\u00e1lise histol\u00f3gica dos \n\ncortes em parafina dos alv\u00e9olos. \n\nAs pe\u00e7as obtidas foram fixadas em formol e sofreram descalcifica\u00e7\u00e3o em \n\nEDTA 18% e em seguida a desidrata\u00e7\u00e3o utilizando uma sequ\u00eancia de \u00e1lcoois. \n\nAp\u00f3s estas etapas, realizaou-se a diafaniza\u00e7\u00e3o com xilol para posterior \n\ninclus\u00e3o em parafina para obten\u00e7\u00e3o de corte sagitais com 5 ?m de espessura e \n\nmontados em l\u00e2minas. Algumas l\u00e2minas foram separadas para a colora\u00e7\u00e3o em \n\nhematoxilina e eosina (HE) e outras para as rea\u00e7\u00f5es de imuno-histoqu\u00edmica. \n\nPreviamente a realiza\u00e7\u00e3o das an\u00e1lises histom\u00e9tricas e imuno-\n\nhistoqu\u00edmicas, as amostras foram codificadas de maneira que somente o \n\norientador conhecera quais grupos pertencem. Um \u00fanico examinador realizou \n\nas an\u00e1lises e o mesmo desconhecia o respectivo grupo da sec\u00e7\u00e3o. \n\nAN\u00c1LISE IMUNOISTOQU\u00cdMICA \n\nO processamento imuno-histoqu\u00edmico foi realizado no Laborat\u00f3rio para o \n\nEstudo de Tecidos Mineralizados (LSMT) da Faculdade de Odontologia de \n\nAra\u00e7atuba \u2013 UNESP (FAPESP, 2012/159122-2; 2015/14688-0). \n\n\n\n29 \n\n \n\nA atividade da peroxidase end\u00f3gena foi inibida com per\u00f3xido de \n\nhidrog\u00eanio. A seguir, as l\u00e2minas passaram pela etapa de recupera\u00e7\u00e3o \n\nantig\u00eanica com tamp\u00e3o fosfato citrato (ph 6.0). Os anticorpos prim\u00e1rios a serem \n\nutilizados foram contra WNT, TRAP, OSTEOCALCINA (Santa Cruz \n\nBiotechnology) e, com o objetivo de se analisar as respostas celulares quanto \n\nao processo de reabsor\u00e7\u00e3o \u00f3ssea (TRAP), regula\u00e7\u00e3o da taxa de renova\u00e7\u00e3o \n\ncelular (turnover \u00f3sseo) (WNT/BETA CATEINA), e mineraliza\u00e7\u00e3o \n\n(osteocalc\u00edna). \n\nForam realizados experimentos de imuno-histoqu\u00edmica utilizando como \n\nm\u00e9todo de detec\u00e7\u00e3o a imunoperoxidase. Foi utilizado o anticorpo secund\u00e1rio \n\nbiotinilado anti-cabra produzido em coelho (Pierce Biotechnology), o \n\namplificador foi a Streptavidina e Biotina (Dako) e a diaminobenzidina (Dako) \n\ncomo crom\u00f3geno. Para cada um dos anticorpos utilizados, foi avaliada a \n\nexpress\u00e3o destas prote\u00ednas semi-quantitativamente \n\nPela atribui\u00e7\u00e3o de diferentes \u201cscores\u201d de acordo com o n\u00famero de \n\nc\u00e9lulas imunomarcadas no processo de reparo alveolar. A an\u00e1lise foi realizada \n\nem microsc\u00f3pio \u00f3ptico (LeicaR DMLB, Heerbrugg, Switzerland), atrav\u00e9s da \n\ncontagem manual das c\u00e9lulas marcadas em \u00e1reas previamente determinadas, \n\nque sabidamente estar\u00e3o envolvidas na din\u00e2mica do tecido \u00f3sseo, e foram \n\nconsideradas positivas as marca\u00e7\u00f5es com diaminobenzidina, tomando-se o \n\ncuidado de se realizar controles negativos para avaliar a especificidade dos \n\nanticorpos (Manrique et al. 2015, Ramalho-Ferreira et al. 2016). \n\n \n\n\n\n30 \n\n \n\nAN\u00c1LISE ESTAST\u00cdSTICA \n\n Para a an\u00e1lise estat\u00edstica dos dados quantitativos foi utilizado o software \n\nSigma Plot 12.3 (San Jose, CA, EUA). A an\u00e1lise da homocedasticidade foi \n\nrealizada pelo teste de Shapiro-Wilk, para distin\u00e7\u00e3o dos dados param\u00e9tricos e \n\nn\u00e3o param\u00e9tricos. Para an\u00e1lise dos dados param\u00e9tricos do micro-CT de \n\nvolume \u00f3sseo (BV), porcentagem do volume \u00f3sseo (BV/TV), espessura do \n\ntrabeculado \u00f3sseo (Tb.Th), separa\u00e7\u00e3o e n\u00famero de trab\u00e9culas (TB.Sp e Tb.N) \n\ne porosidade total (Po-tot), foi utilizado o teste Shapiro-Wilk e p\u00f3s-teste Tukey. \n\nAdotou-se o n\u00edvel de signific\u00e2ncia de p&lt;0,05. \n\n \n\n \n\n1.5 Resultados  \n\n \n\nAN\u00c1LISE POR MICRO-CT  \n\nQuantitativamente, na avalia\u00e7\u00e3o microtomogr\u00e1fica referente a medida do \n\nvolume \u00f3sseo (BV) no grupo SHAM obtida em m\u00e9dia, foi de 124,120mm\u00b3, no \n\ngrupo ORQ foi 65,006mm\u00b3 e ORQTRAT 157,915mm\u00b3, em que o volume se \n\napresentou semelhante ao grupo SHAM, por\u00e9m com diferen\u00e7a estatisticamente   \n\nsignificante entre em compara\u00e7\u00e3o ao ORQ (p<0,05, Tukey test). (Figura 7). \n\nQuando avaliado a porcentagem de volume \u00f3sseo (BV/TV) o grupo ORQ \n\n(59,69%) se mostrou inferior ao grupo SHAM (60,35%) e ORQTRAT (67,19%), \n\n(p=0,749, Shapiro-Wilk) (Figura 8). \n\n Referente \u00e0s trab\u00e9culas \u00f3sseas do osso alveolar em repara\u00e7\u00e3o, a \n\nespessura trabecular (Tb.Th) mostrou resultados aproximados entre os grupos \n\n\n\n31 \n\n \n\nSHAM (1,454mm) e ORQTRAT (1,873mm), os quais apresentaram resultados \n\nmelhores em compara\u00e7\u00e3o ao grupo ORQ (1,212mm) (p=0,057, Shapiro Wilk) \n\n(Figura 9). Seguindo este mesmo padr\u00e3o, a separa\u00e7\u00e3o entre as trab\u00e9culas \n\n(Tb.Sp) apresentou-se aproximado os valores m\u00e9dios do grupo SHAM \n\n(1,103mm) e ORQTRAT (1,067mm), com diminui\u00e7\u00e3o para o grupo ORQ \n\n(0,764mm), (p=0,073, Shapiro-Wilk) (Figura 10). Quanto ao n\u00famero de \n\ntrab\u00e9culas (Tb.N), foi obtido uma m\u00e9dia de 0,417 para SHAM com valor \n\npr\u00f3ximo ao ORQ de 0,496, e diminui\u00e7\u00e3o no n\u00famero para o grupo ORQTRAT, \n\ncom 0,358. Apresentando diferen\u00e7a estat\u00edstica entre os grupos ORQ e \n\nORQTRAT (p<0,05, Tukey test) (Figura 11). \n\n Em rela\u00e7\u00e3o \u00e0 porosidade \u00f3ssea do alv\u00e9olo em repara\u00e7\u00e3o avaliada \n\natrav\u00e9s da porcentagem de porosidade total (Po-tot), os valores foram 46,292% \n\n(SHAM), 40,310% (ORQ) e 32,812% (ORQTRAT) mostrando ent\u00e3o menor \n\npercentual de porosidade no grupo ORQTRAT (p=0,496, Shapiro-Wilk) (Figura \n\n12). \n\n \n\nAN\u00c1LISE HISTOL\u00d3GICA \n\nFoi obtida a fotomicrografia das l\u00e2minas histol\u00f3gicas do per\u00edodo de 42 dias de \n\ntodos os grupos atrav\u00e9s da objetiva de 40x, que possibilitou analisar que o \n\ngrupo SHAM teve uma boa neoforma\u00e7\u00e3o \u00f3ssea, apresentando pouco tecido \n\nconjuntivo o que representa pouco espa\u00e7o trabecular (Figura 13A). J\u00e1 nas \n\nimagens obtidas do grupo ORQ, foi poss\u00edvel notar as imagens com os piores \n\nresultados, com pobre neoforma\u00e7\u00e3o \u00f3ssea e rica em tecido conjuntivo, \n\ncaracterizando grandes espa\u00e7os intertrabeculares (Figura 13E). Analisando as \n\n\n\n32 \n\n \n\nl\u00e2minas dos animais tratados com teriparatida (ORQTRAT), notou-se os \n\nmelhores resultados histol\u00f3gicos por HE, onde foi poss\u00edvel notar uma grande \n\nneoforma\u00e7\u00e3o \u00f3ssea e pequenas \u00e1reas de tecido conjuntivo (Figura 13I). \n\n \n\nAN\u00c1LISE IMUNOHISTOQU\u00cdMICA \n\nA t\u00e9cnica de imuno-histoqu\u00edmica foi realizada aos 42 dias em todos os \n\ngrupos experimentais, a fim de avaliar o processo da remodela\u00e7\u00e3o \u00f3ssea \n\natrav\u00e9s da marca\u00e7\u00e3o das prote\u00ednas WNT/Beta-catenina, Osteocalcina e Trap. \n\n \n\nGRUPO SHAM: \n\nMarca\u00e7\u00e3o pela WNT: As fotomicrografias obtidas aos 42 dias ap\u00f3s a extra\u00e7\u00e3o \n\nmostraram forte marca\u00e7\u00e3o (3) (Figura 13B). \n\nMarca\u00e7\u00e3o pela osteocalc\u00edna: as fotomicrografias obtidas aos 42 dias ap\u00f3s a \n\nextra\u00e7\u00e3o mostraram-se moderadamente marcadas (2) (Figura 13C). \n\nMarca\u00e7\u00e3o pela TRAP: As fotomicrografias obtidas aos 42 dias ap\u00f3s a exodontia \n\nmostraram marca\u00e7\u00e3o moderada (2) (Figura 13D). \n\n \n\nGRUPO ORQ: \n\nMarca\u00e7\u00e3o pela WNT: As fotomicrografias obtidas aos 42 dias ap\u00f3s a extra\u00e7\u00e3o \n\nmostraram moderada marca\u00e7\u00e3o (2) (Figura 13F). \n\nMarca\u00e7\u00e3o pela osteocalc\u00edna: as fotomicrografias obtidas aos 42 dias ap\u00f3s a \n\nextra\u00e7\u00e3o mostraram-se moderadamente marcadas (2) (Figura 13G). \n\nMarca\u00e7\u00e3o pela TRAP: As fotomicrografias obtidas aos 42 dias ap\u00f3s a exodontia \n\nmostraram marca\u00e7\u00e3o moderada (2) (Figura 13H). \n\n\n\n33 \n\n \n\n \n\nGRUPO ORQTRAT: \n\nMarca\u00e7\u00e3o pela WNT: As fotomicrografias obtidas aos 42 dias ap\u00f3s a extra\u00e7\u00e3o \n\nmostraram forte marca\u00e7\u00e3o (3) (Figura 13J). \n\nMarca\u00e7\u00e3o pela osteocalc\u00edna: as fotomicrografias obtidas aos 42 dias ap\u00f3s a \n\nextra\u00e7\u00e3o mostraram-se fortemente marcadas (3) (Figura 13K). \n\nMarca\u00e7\u00e3o pela TRAP: As fotomicrografias obtidas aos 42 dias ap\u00f3s a exodontia \n\nmostraram marca\u00e7\u00e3o fraca (1) (Figura 13L). \n\n \n\n \n\n1.6 Discuss\u00e3o \n\nEste estudo indicou que o tratamento com teriparatida melhorou o reparo \n\n\u00f3sseo alveolar em 42 dias p\u00f3s exod\u00f4ntico nos animais com osteoporose \n\ninduzida e tratados com teriparatida. Este tratamento se mostrou capaz de \n\naumentar a atividade celular ligada ao reparo \u00f3sseo e de aumentar as \n\ncaracter\u00edsticas histol\u00f3gicas de neoforma\u00e7\u00e3o \u00f3ssea quando comparado aos \n\nratos induzidos \u00e0 osteoporose sem tratamento. \n\nA teriparatida tem se mostrado eficiente no tratamento da osteoporose, \n\nreduzindo o risco de fraturas e aumentando a densidade \u00f3ssea mineral dos \n\nossos longos (Kim et al. 2017). Embora, pouco se saiba dos efeitos nos ossos \n\nmaxilares.  \n\nO presente estudo apresentou melhora dos padr\u00f5es histol\u00f3gicos do osso \n\nalveolar em repara\u00e7\u00e3o dos animais tratados com teriparatida. Foi poss\u00edvel notar \n\n\n\n34 \n\n \n\natrav\u00e9s dos cortes histol\u00f3gicos um melhor padr\u00e3o trabecular com pouca \n\npresen\u00e7a de tecido conjuntivo. \n\nQuando analisado o reparo \u00f3sseo alveolar dos ratos induzidos \u00e0 \n\nosteoporose neste estudo, foi poss\u00edvel observar que os 42 dias do tratamento \n\ncom teriparatida levou a uma intensa (3) marca\u00e7\u00e3o de WNT assim como no \n\ngrupo SHAM indicando um padr\u00e3o normal e mais alto quando comparado ao \n\ngrupo ORQ (2) de prolifera\u00e7\u00e3o e migra\u00e7\u00e3o das c\u00e9lulas osteog\u00eanicas. Quando \n\nanalisado a marca\u00e7\u00e3o da osteocalc\u00edna os resultados tamb\u00e9m foram favor\u00e1veis, \n\nonde foi poss\u00edvel notar uma forte marca\u00e7\u00e3o (3) no grupo ORQTRAT, sendo \n\nesta superior \u00e0 encontrada nos grupos ORQ e SHAM (2), indicando que o \n\ntratamento foi capaz de aumentar a secre\u00e7\u00e3o dessa prote\u00edna pelos \n\nosteoblastos melhorando a atividade osteog\u00eanica. Ainda, foi observada uma \n\nmaior atividade de TRAP (2) nos grupos ORQ e SHAM quando comparado ao \n\ngrupo ORQTRAT (3), mostrando tamb\u00e9m que o tratamento foi capaz de regular \n\na atividade osteocl\u00e1stica, auxiliando na manuten\u00e7\u00e3o da massa \u00f3ssea. Esses \n\ndados s\u00e3o consistentes com os da literatura previamente estudada que relata \n\numa melhora do anabolismo \u00f3sseo e diminui\u00e7\u00e3o da reabsor\u00e7\u00e3o \u00f3ssea \n\nproporcionada pelo tratamento com a teriparatida (Murray et al. 2005). \n\nAinda, \u00e9 sabido que a qualidade do tecido \u00f3sseo \u00e9 fundamental para o \n\nsucesso da reabilita\u00e7\u00e3o (Jaffin and Berman 1991, Jemt et al. 1992). Tem sido \n\nsugerido que a densidade \u00f3ssea, volume \u00f3sseo e volume do osso trabecular \n\ns\u00e3o fundamentais par\u00e2metros na taxa de sucesso dos implantes \n\nosseointegr\u00e1veis (Shapurian et al. 2006, Parfitt et al. 1987). A microtomografia \n\n\n\n35 \n\n \n\nse apresenta como padr\u00e3o ouro de avalia\u00e7\u00e3o desses par\u00e2metros \u00f3sseos, ainda \n\nque esta n\u00e3o seja usada clinicamente (Burghardt, Link, and Majumdar 2011).  \n\nDe fato, a micro-ct aos 60 dias do reparo alveolar mostrou que o \n\ntratamento proposto foi capaz de melhorar a porcentagem de volume \u00f3sseo \n\n(BV/TV), a espessura das trab\u00e9culas (Tb.Th), a separa\u00e7\u00e3o das trab\u00e9culas \n\n(Tb.Sp) e, com diferen\u00e7a estat\u00edstica, o volume \u00f3sseo (BV) (p>0,05, Tukey test). \n\nAl\u00e9m de diminuir a quantidade de trab\u00e9culas (Tb.N) e a porosidade \u00f3ssea \n\n(Po.Tot). Estes dados sugerem que o tratamento com a teriparatida pode \n\nmelhorar as caracter\u00edsticas microestruturais do osso alveolar em repara\u00e7\u00e3o, \n\ncaracterizando uma melhor qualidade do osso alveolar. \n\nO maior volume \u00f3sseo neoformado encontrado para o grupo ORQTRAT, \n\ncompactua com os valores de percentual de volume \u00f3sseo, tendo assim, \n\nresultados que mostram maior neoforma\u00e7\u00e3o \u00f3ssea neste grupo. Os par\u00e2metros \n\nde espessura do trabeculado, n\u00famero e espa\u00e7amento das trab\u00e9culas e a \n\nporosidade total tamb\u00e9m foram avaliados. Um maior volume do osso \n\ntrabecular, menor n\u00famero e espa\u00e7o entre as trab\u00e9culas, assim como menor \n\nporcentagem de porosidade total, \u00e9 considerado um osso de melhor qualidade \n\n(Bouxsein et al., 2010). \n\nDevido \u00e0 alta incidencia de osteoporose no homem, uma quantidade alta \n\nde tratamentos tem sido propostos (Riggs, Khosla, and Melton 1998). \n\nEntretanto, pouco \u00e9 discutido sobre o efeito dessas drogas no turnover do osso \n\nalveolar. \u00c9 sabido que os bisfosfonatos, principalmente o alendronato, s\u00e3o as \n\ndrogas mais usadas no tratamento das osteoporoses, tendo bons resultados na \n\npreven\u00e7\u00e3o de fraturas vertebrais (Wells et al. 2008). Embora seu uso a longo \n\n\n\n36 \n\n \n\ntermo promova osteonecrose dos maxilares (Ruggiero and Drew 2007), e de \n\nn\u00e3o ser a via de tratamento ideal na osteoporose em homens, uma vez que \n\nesta droga diminui a reabsor\u00e7\u00e3o \u00f3ssea e no homem a deficiente neoforma\u00e7\u00e3o \n\n\u00f3ssea que se da como etiologia desta patologia (Gagnon; Li; Ebeling, 2008). \n\nAssim, tratamentos que estimulem a neoforma\u00e7\u00e3o \u00f3ssea necessitam de \n\nmais estudos, os tratamentos para osteoporose ainda n\u00e3o foram estudados em \n\nhomens como em mulheres, e somente algumas terapias foram aprovadas \n\npara a aplica\u00e7\u00e3o em homens. Destes se incluem os bisfosfonatos e teriparatida \n\n(Gagnon; Li; Ebeling, 2008). Sendo a teriparatida ent\u00e3o o \u00fanico tratamento \n\nanab\u00f3lico aprovado para o uso em homens com osteoporose (Cheng; Gupta, \n\n2012). \n\nAssim, diante do exposto e dos limites deste estudo in vivo, foi poss\u00edvel \n\nconcluir que o tratamento com teriparatida em ratos orquiectomizados aumenta \n\no volume e melhora a qualidade \u00f3ssea no reparo alveolar. \n\n \n\n \n\n  \n\n\n\n37 \n\n \n\n1.7 Refer\u00eancias \n \n \n \n\nAmin, S.; Zhang, Y.; Felson, D.T.; Sawin, C.T.; Hannan, M.T.; Wilson, P.W.; \n\nKiel, D.P. (2006). Estradiol, testosterone, and the risk for hip fractures in \n\nelderly men from the Framingham Study. Am J Med, v119, n5, p.426-433. \n\nBilezikian, J.P. (2006). Osteonecrosis of the jaw - do bisphosphonates pose \n\na risk? N Engl J Med, v355, n22, p2278-2281. \n\nBouxsein, M. L., S. K. Boyd, B. A. Christiansen, R. E. Guldberg, K. J. \n\nJepsen, and R. M\u00fcller. (2010). \"Guidelines for assessment of bone \n\nmicrostructure in rodents using micro-computed tomography.\"  J Bone Miner \n\nRes 25 (7):1468-86. \n\nBurge, R.; Dawson-Hughes, B.; Solomon, D.H.; Wong, J.B.; King, A.; \n\nTosteson, A. (2007). Incidence and Economic Burden of Osteoporosis-\n\nRelated Fractures in the United States, 2005-2025. Journal of bone and \n\nmineral research, v2, n3, p.465-475. \n\nBurghardt, A. J., T. M. Link, and S. Majumdar. (2011). \"High-resolution \n\ncomputed tomography for clinical imaging of bone microarchitecture.\"  Clin \n\nOrthop Relat Res 469 (8):2179-93. \n\nCarvalho, A.C.P.; Okamoto, T. (1987). Cirurgia bucal: fundamentos \n\nexperimentais aplicados a cl\u00ednica. S\u00e3o Paulo: Panamericana. \n\nCheng, M.L.; Gupta, V. (2012). Teriparatide \u2013 Indications beyond \n\nosteoporosis. Indian Journal of Endocrinology and Metabolism, v16, n3, \n\np343-348. \n\n\n\n38 \n\n \n\nCooper, C.; Melton III, L.J. (1992). Epidemiology of osteoporosis. Trends \n\nEndocrinol Metab, v3, p.224-229. \n\nDuque, G.; El Abdaimi, K.; Henderson, J.E.; Lomri, A.; Kremer, R. (2004). \n\nVitamin D inhibits Faz ligand-induced apoptosis in human osteoblasts by \n\nregulating components of both the mitochondrial and Fas-related pathways. \n\nBone, v35, n1, p.57-64. \n\nDuque, G.; Macoritto, M.; Dion, N.; Ste-Marie, L.G.; Kremer, R. (2005). \n\n1,25(OH)2D3 acts as abone-forming agent in the hormone-independent \n\nsenescence-accelerated mouse(SAM-P/6). Am J Physiol Endocrinol Metab, \n\nv288, n4, p.E723-E730. \n\nElsubeihi, E.S.; Heersch, J.M.N.; (2002). Effects of postmenopausal \n\nosteoporosis in the mandible. In: Zarb, G.; Lekholm, U.; Albrektsson, T.; \n\nTenenbaum, H. Aging, osteoporosis and dental implants. London: \n\nQuintessence Books, p.207\u2013215. \n\nErsan, N.; van Ruijven, L.J.; Bronckers, A.L.; Olga\u00e7, V.; Ilg\u00fcy, D.; Everts, V. \n\n(2014). Teriparatide and the treatment of bisphosphonate-related \n\nosteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol, v43, n1, \n\n20130144. \n\nFalahati-Nini, A.; Riggs, B.L.; Atkinson, E.J.; O\u2019Fallon, W.M.; Eastell, R.; \n\nKhosla, S.(2000). Relative contributions of testosterone and estrogen in \n\nregulating bone resorption and formation in normal elderly men. Journal of \n\nClinical Investigation, v106, n12, p.1553-1560. \n\n\n\n39 \n\n \n\nGagnon, C.; Li, V.; Ebeling, P.R. (2008). Osteoporosis in men: its \n\npathophysiology and the role of teriparatide in its treatment. Clinical \n\ninterventions in aging, v3, n4, p.635-645. \n\nHo, Y.V.; Frauman, A.G.; Thomson, W.; Seeman, E. (2000). Effects of \n\nalendronate on bone densityin men with primary and secondary \n\nosteoporosis. Osteoporos Int, v11, n2, p.98-10. \n\nJaffin, R. A., and C. L. Berman. (1991). \"The excessive loss of Branemark \n\nfixtures in type IV bone: a 5-year analysis.\"  J Periodontol 62 (1):2-4. \n\nJemt, T., K. Book, B. Lind\u00e9n, and G. Urde. (1992). \"Failures and \n\ncomplications in 92 consecutively inserted overdentures supported by \n\nBr\u00e5nemark implants in severely resorbed edentulous maxillae: a study from \n\nprosthetic treatment to first annual check-up.\"  Int J Oral Maxillofac Implants \n\n7 (2):162-7. \n\nKhosla, S.; Amin, S.;  Orwoll, E. (2008). Osteoporosis in Men. Endocrine \n\nReviews, v29, n4, p.441\u2013464. \n\nKim SM, Kang KC, Kim JW, Lim SJ, Hahn MH. (2017). Current Role and \n\nApplication of Teriparatide in Fracture Healing of Osteoporotic Patients: A \n\nsystematic Review. J Bone Metab. Feb;24(1):65-73. \n\nLeder, B.Z.; LeBlanc, K.M.; Schoenfeld, D.A.; Eastell, R.; Finkelstein, J.S. \n\n(2010). Differential effects of androgens and estrogens on bone turnover in \n\nnormal men. J Clin Endocrinol Metab, v88, n1, p.204-210. \n\nLips, P. (2001). Vitamin D deficiency and secondary hyperparathyroidism in \n\nthe elderly:consequences for bone loss and fractures and therapeutic \n\nimplications. Endocr Rev, v22, n4, p.477-501. \n\n\n\n40 \n\n \n\nManrique, N., C. C. Pereira, E. R. Luvizuto, M.el P S\u00e1nchez, T. Okamoto, R. \n\nOkamoto, D. H. Sumida, and C. Antoniali. (2015). \"Hypertension modifies \n\nOPG, RANK, and RANKL expression during the dental socket bone healing \n\nprocess in spontaneo Ramalho-Ferreira, G., L. P. Faverani, G. A. Momesso, \n\nE. \n\nMurray TM, Rao LG, Divieti P, et al. (2005). Parathyroid hormone secretion \n\nand action: evidence for discrete receptors for the carboxyl-terminal region \n\nand related biological actions of carboxyl-terminal ligands. Endocr \n\nRev;26:78\u2013113. \n\nOkamoto T, Russo MC. (1973) Wound healing following tooth extraction: \n\nhistochemical study in rats. Rev Fac Odontol Ara\u00e7atuba; v2, p.153-169. \n\nOrwoll, E.; Ettinger, M.; Weiss, S.; Miller, P.; Kendler, D.; Graham, J.; \n\nAdami, S.; Weber, K.; Lorenc, R.; Pietschmann, P.; Vandormael, K.; \n\nLombardi, A. (2000). Alendronate for the treatment of osteoporosis in men. \n\nN Engl J Med, v343, n9, p.604-610. \n\nOrwoll, E.; Lambert, L.C.; Marshall, L.M.; Phipps, K.; Blank, J.; Barrett-\n\nConnor, E.; Cauley, J.; Esnrud, K.; Cummings, S. (2006). Testosterone and \n\nEstradiol among Older Men. The Journal of Clinical Endocrinology &amp; \n\nMetabolism, v91, n4, p.1336-1344. \n\nParfitt, A. M., M. K. Drezner, F. H. Glorieux, J. A. Kanis, H. Malluche, P. J. \n\nMeunier, S. M. Ott, and R. R. Recker. (1987). \"Bone histomorphometry: \n\nstandardization of nomenclature, symbols, and units. Report of the ASBMR \n\nHistomorphometry Nomenclature Committee.\"  J Bone Miner Res 2 (6):595-\n\n610. \n\n\n\n41 \n\n \n\nPetroianu, A.; Veloso, D.F.; Alberti, L.R.; Figueiredo, J.A.; Rodrigues, F.H. \n\n(2010). Is there a relationship between physical performance and \n\norchiectomy? Andrologia, v42, n5 p.302-304. \n\nR. Luvizuto, I. de Oliveira Puttini, and R. Okamoto. (2016). \"Effect of \n\nantiresorptive drugs in the alveolar bone healing. A histometric and \n\nimmunohistochemical study in ovariectomized rats.\"  Clin Oral Investig. doi: \n\n10.1007/s00784-016-1909-x.usly hypertensive rats.\"  Clin Oral Investig 19 \n\n(6):1319-27. \n\nRamalho-Ferreira G, Faverani LP, Prado FB, Garcia IR Jr &amp; Okamoto R: \n\n(2015). Raloxifene enhances peri-implant bone healing in osteoporotic rats. \n\nInt J Oral Maxillofac Surg. 44(6):798-805. \n\nRamalho-Ferreira, G.; Faverani, L.P.; Grossi-Oliveira, G.A.; Okamoto,T.; \n\nOkamoto, R. (2015). Alveolar bone dynamics in osteoporotic rats treated \n\nwith raloxifene or alendronate: confocal microscopy analysis. Journal of \n\nBiomedical Optics, v20, n3, p.038003-1 \u2013 038003-7. \n\nRiggs, B. L., S. Khosla, and L. J. Melton. (1998). \"A unitary model for \n\ninvolutional osteoporosis: estrogen deficiency causes both type I and type II \n\nosteoporosis in postmenopausal women and contributes to bone loss in \n\naging men.\"  J Bone Miner Res 13 (5):763-73. \n\nRinge, J.D.; Faber, H.; Farahmand, P.; Dorst, A. (2006). Efficacy of \n\nrisedronate in men with primary and secondary osteoporosis: results of a 1-\n\nyear study. Rheumatol Int, v26, n5, p.427-431. \n\nRuggiero, S. L., and S. J. Drew. (2007). \"Osteonecrosis of the jaws and \n\nbisphosphonate therapy.\"  Journal of dental research 86 (11):1013-1021. \n\n\n\n42 \n\n \n\nVon Wowern N &amp; Kollerup G (1992). Symptomatic osteoporosis: a risk factor \n\nfor residual ridge reduction of the jaws. J Prosthet Dent. 67(5):656-60. \n\nWells, G. A., A. Cranney, J. Peterson, M. Boucher, B. Shea, V. Robinson, D. \n\nCoyle, and P. Tugwell. (2008). \"Alendronate for the primary and secondary \n\nprevention of osteoporotic fractures in postmenopausal women.\"  Cochrane \n\nDatabase Syst Rev (1):CD001155. \n\nWells, G. A., A. Cranney, J. Peterson, M. Boucher, B. Shea, V. Robinson, D. \n\nCoyle, and P. Tugwell. (2008). \"Alendronate for the primary and secondary \n\nprevention of osteoporotic fractures in postmenopausal women.\"  Cochrane \n\nDatabase Syst Rev (1):CD001155. \n\n \n\n \n\n  \n\n\n\n43 \n\n \n\nAgradecimentos \n\nOs autores agradecem \u00e0 FAPESP pelo aux\u00edlio pesquisa regular concedido (# \n\n2015/14688-0). \n\n \n\n  \n\n\n\n44 \n\n \n\n1.8 Lista de Tabelas \n\n \n\nTabela 1 \u2013 Grupos experimentais de acordo com o tratamento com \n\nTeripatida. \n\nSHAM (n= 16), ratos submetidos \u00e0 cirurgia fict\u00edcia e n\u00e3o receberam \n\ntratamento medicamentoso. \n\nORQ (n=16), ratos submetidos \u00e0 orquiectomia que n\u00e3o receberam tratamento \n\nmedicamentoso. \n\nORQTRAT (n=16), ratos submetidos \u00e0 orquiectomia que receberam \n\nteriparatida (dose 0,5 mcg/kg/dia). \n\n \n\n \n\n\n\n45 \n\n \n\n1.9 Lista de Figuras \n\n \n\nFigura 1 \u2013 Linha do tempo experimental \n\n \n\nFigura 2 \u2013 A: Antissepsia com PVPI em ambos os sacos escrotais; B: Incis\u00e3o; C e D: \n\nExposi\u00e7\u00e3o de ambos escrotos; E: Laqueamento do ducto deferente e do ped\u00edculo \n\nvascular; F: Remo\u00e7\u00e3o de ambos escrotos com auxilio de uma tesoura; G: Sutura; H: \n\nAmbos escrotos removidos (Orquiectomia). \n\n\n\n46 \n\n \n\n \n\nFigura 3 \u2013 1: Antissepsia com PVPI na \u00e1rea cirurgica; 2: Luxa\u00e7\u00e3o do dente com \n\nalavanca 3: Luxa\u00e7\u00e3o do elemento dental com f\u00f3rceps adaptado; 4: exodontia. \n\n \n\nFigura 4 \u2013 Imagem em 3 dimens\u00f5es obtida atrav\u00e9s do software DataViewer da micro-\n\nct. \n\n\n\n47 \n\n \n\n \n\nFigura 5 \u2013 Sele\u00e7\u00e3o da \u00e1rea de interesse da an\u00e1lise de micro-ct atrav\u00e9s do software \n\nCT Analyzer. \n\n \n\n\n\n48 \n\n \n\nFigura 6 \u2013 Utiliza\u00e7\u00e3o da ferramenta thershould para mensura\u00e7\u00f5es da micro-ct atrav\u00e9s \n\nde escalas de cinza feita pelo software CT Analyzer. \n\n \n\nFigura 7 \u2013 Quantifica\u00e7\u00e3o do volume \u00f3sseo. Volume equiparados do SHAM e ORQ. \n\nTeste de Shapiro-Wilk e p\u00f3s-teste de Tukey. \n\n  \n\n \n\nFigura 8 \u2013 Quantifica\u00e7\u00e3o do percentual de volume \u00f3sseo. Percentuais aproximados. \n\nTeste de Shapiro-Wilk e p\u00f3s-teste de Tukey.  \n\n\n\n49 \n\n \n\n \n\n \n\nFigura 9 \u2013 Quantifica\u00e7\u00e3o da espessura trabecular. Valores similares do SHAM e \n\nORQTRAT Teste de Shapiro-Wilk e p\u00f3s-teste de Tukey. (p>0,05). \n\n  \n\nFigura 10 \u2013 Quantifica\u00e7\u00e3o da separa\u00e7\u00e3o entre as trab\u00e9culas. Valores maiores para \n\nSHAM e ORQTRAT e menor para o grupo ORQ. Teste de Shapiro-Wilk e p\u00f3s-teste de \n\nTukey.  \n\n\n\n50 \n\n \n\n \n\nFigura 11 \u2013 Quantifica\u00e7\u00e3o do n\u00famero de trab\u00e9culas. Valor maior para ORQ e menor \n\npara SHAM e ORQTRAT. Teste de Shapiro-Wilk e p\u00f3s-teste de Tukey. (p>0,05). \n\n \n\n\n\n51 \n\n \n\nFigura 12 \u2013 Quantifica\u00e7\u00e3o do percentual de porosidade total. Valor compat\u00edvel \n\ncom osso mais poroso para o grupo ORQ e menos poroso para SHAM e \n\nORQTRAT (p>0,05).  \n\n \n\n\n\n52 \n\n \n\n                           \n\nFigura 13 \u2013 Prancha com as imagens histol\u00f3gicas e imunohistoqu\u00edmicas dos alv\u00e9olos \n\nem repara\u00e7\u00e3o no per\u00edodo de 42 dias ap\u00f3s a exodontia em aumento de 40x. \n\n \n\n \n\n\n\n53 \n\n \n\n \n\n \n\n \n\n \n\nANEXO\n\n\n\n54 \n\n Anexo \n\n \n\n2.0 Anexo A - Comit\u00ea de \u00e9tica \n\n \n\n \n\n  \n\n\n\n55 \n\n Anexo \n\n \n\n2.1 Anexo B - Normas para publica\u00e7\u00e3o \ndo peri\u00f3dico Clinical Oral Implants \nResearch \n\n \n\n \n\nAuthor Guidelines \n\n \n\nContent of Author Guidelines: 1. General, 2. Ethical Guidelines, 3. Submission \n\nof Manuscripts, 4. Manuscript Types Accepted, 5. Manuscript Format and \n\nStructure, 6. After Acceptance.  \n\n \n\nUseful Websites: Submission Site, Articles published in Clinical Oral Implants \n\nResearch, Author Services, Wiley-Blackwell\u2019s Ethical Guidelines, Guidelines for \n\nFigures \n\n \n\nThe journal to which you are submitting your manuscript employs a plagiarism \n\ndetection system. By submitting your manuscript to this journal you accept that \n\nyour manuscript may be screened for plagiarism against previously published \n\nworks. \n\n \n\n1. GENERAL \n\nClinical Oral Implants Research conveys scientific progress in the field of \n\nimplant dentistry and its related areas to clinicians, teachers and researchers \n\nconcerned with the application of this information for the benefit of patients in \n\nneed of oral implants. The journal addresses itself to clinicians, general \n\npractitioners, periodontists, oral and maxillofacial surgeons and prosthodontists, \n\nas well as to teachers, academicians and scholars involved in the education of \n\nprofessionals and in the scientific promotion of the field of implant dentistry. \n\n \n\nClinical Oral Implants Research publishes: \n\nOriginal research articles of high scientific merit in the field of material sciences, \n\nphysiology of wound healing, biology of tissue integration of implants, diagnosis \n\nand treatment planning, prevention of pathologic processes jeopardizing the \n\n\n\n56 \n\n Anexo \n\n \n\nlongevity of implants, clinical trials on implant systems, stoma-tognathic \n\nphysiology related to oral implants, new developments in therapeutic concepts \n\nand prosthetic rehabilitation. \n\n \n\nReview articles by experts on new developments in basic sciences related to \n\nimplant dentistry and clinically applied concepts. \n\n \n\nCase reports and case series only if they provide or document new fundamental \n\nknowledge. \n\n \n\nNovel developments if they provide a technical novelty for any implant system. \n\n \n\nShort communications of important research findings in a concise format and for \n\nrapid publication. \n\n \n\nTreatment rational by experts with evidence-based treatment approach. \n\n \n\nPlease read the instructions below carefully for details on the submission of \n\nmanuscripts, the journal's requirements and standards as well as information \n\nconcerning the procedure after a manuscript has been accepted for publication \n\nin Clinical Oral Implants Research. Authors are encouraged to visit Wiley-\n\nBlackwell Author Services  for further information on the preparation and \n\nsubmission of articles and figures. \n\n \n\n2. ETHICAL GUIDELINES \n\nClinical Oral Implants Research adheres to the below ethical guidelines for \n\npublication and research.  \n\n \n\n2.1. Authorship and Acknowledgements \n\nAuthors submitting a paper do so on the understanding that the manuscript \n\nhave been read and approved by all authors and that all authors agree to the \n\nsubmission of the manuscript to the Journal. ALL named authors must have \n\nmade an active contribution to the conception and design and/or analysis and \n\n\n\n57 \n\n Anexo \n\n \n\ninterpretation of the data and/or the drafting of the paper and ALL must have \n\ncritically reviewed its content and have approved the final version submitted for \n\npublication. Participation solely in the acquisition of funding or the collection of \n\ndata does not justify authorship. \n\n \n\nClinical Oral Implants Research adheres to the definition of authorship set up by \n\nThe International Committee of Medical Journal Editors (ICMJE). According to \n\nthe ICMJE authorship criteria should be based on 1) substantial contributions to \n\nconception and design of, or acquisition of data or analysis and interpretation of \n\ndata, 2) drafting the article or revising it critically for important intellectual \n\ncontent and 3) final approval of the version to be published. Authors should \n\nmeet conditions 1, 2 and 3. \n\n \n\nUp to 6 authors are accepted without need for justification. In the case of a \n\nspecific and detailed justification of the role of every author, up to 8 authors may \n\nbe mentioned. It is a requirement that all authors have been accredited as \n\nappropriate upon submission of the manuscript. Contributors who do not qualify \n\nas authors should be mentioned under Acknowledgements. \n\n \n\nAcknowledgements: Under acknowledgements please specify contributors to \n\nthe article other than the authors accredited. Acknowledge only persons who \n\nhave made substantive contributions to the study. Authors are responsible for \n\nobtaining written permission from everyone acknowledged by name because \n\nreaders may infer their endorsement of the data and conclusions. \n\n \n\n2.2. Ethical Approvals \n\nExperimentation involving human subjects will only be published if such \n\nresearch has been conducted in full accordance with ethical principles, \n\nincluding the World Medical Association Declaration of Helsinki (version, 2008) \n\nand the additional requirements, if any, of the country where the research has \n\nbeen carried out. Manuscripts must be accompanied by a statement that the \n\nexperiments were undertaken with the understanding and written consent of \n\neach subject and according to the above mentioned principles. A statement \n\nregarding the fact that the study has been independently reviewed and \n\napproved by an ethical board should also be included. Editor reserve the right \n\n\n\n58 \n\n Anexo \n\n \n\nto reject papers if there are doubts as to whether appropriate procedures have \n\nbeen used. \n\n \n\nWhen experimental animals are used the methods section must clearly indicate \n\nthat adequate measures were taken to minimize pain or discomfort. \n\nExperiments should be carried out in accordance with the Guidelines laid down \n\nby the National Institute of Health (NIH) in the USA regarding the care and use \n\nof animals for experimental procedures or with the European Communities \n\nCouncil Directive of 24 November 1986 (86/609/EEC) and in accordance with \n\nlocal laws and regulations. \n\n \n\n2.3 Clinical Trials \n\nClinical trials should be reported using the CONSORT guidelines available at \n\nwww.consort-statement.org. A CONSORT checklist should also be included in \n\nthe submission material. \n\n \n\nClinical Oral Implants Research encourages authors submitting manuscripts \n\nreporting from a clinical trial to register the trials in any of the following free, \n\npublic clinical trials registries: www.clinicaltrials.gov, \n\nhttp://clinicaltrials.ifpma.org/clinicaltrials, http://isrctn.org/. The clinical trial \n\nregistration number and name of the trial register will then be published with the \n\npaper. \n\n \n\n2.4 Conflict of Interest and Source of Funding \n\nClinical Oral Implants Research requires that sources of institutional, private \n\nand corporate financial support for the work within the manuscript be fully \n\nacknowledged, and any potential conflicts of interest noted. Suppliers of \n\nmaterials should be named and their location (town, state/county, country) \n\nincluded. Information concerning conflict of interest and sources of funding \n\nshould be included under Acknowledgements. \n\n \n\n2.5 Appeal of Decision \n\nThe decision on a paper is final and cannot be appealed. \n\n \n\n\n\n59 \n\n Anexo \n\n \n\n2.6 Permissions \n\nIf all or parts of previously published illustrations are used, permission must be \n\nobtained from the copyright holder concerned. It is the author's responsibility to \n\nobtain these in writing and provide copies to the Publishers. \n\n \n\n2.7 Copyright Assignment \n\nAuthors submitting a paper do so on the understanding that the work and its \n\nessential substance have not been published before and is not being \n\nconsidered for publication elsewhere. \n\n \n\nIf your paper is accepted, the author identified as the formal corresponding \n\nauthor for the paper will receive an email prompting them to login into Author \n\nServices; where via the Wiley Author Licensing Service (WALS) they will be \n\nable to complete the license agreement on behalf of all authors on the paper. \n\n \n\nFor authors signing the copyright transfer agreement \n\nIf the OnlineOpen option is not selected the corresponding author will be \n\npresented with the copyright transfer agreement (CTA) to sign. The terms and \n\nconditions of the CTA can be previewed in the samples associated with the \n\nCopyright FAQs below: \n\nCTA Terms and Conditions \n\nhttp://authorservices.wiley.com/bauthor/faqs_copyright.asp \n\nFor authors choosing OnlineOpen \n\nIf the OnlineOpen option is selected the corresponding author will have a choice \n\nof the following Creative Commons License Open Access Agreements(OAA): \n\n \n\nCreative Commons Attribution Non-Commercial License OAA \n\nCreative Commons Attribution Non-Commercial -NoDerivs License OAA \n\n \n\nTo preview the terms and conditions of these open access agreements please \n\nvisit the Copyright FAQs hosted on Wiley Author Services \n\nhttp://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit \n\n\n\n60 \n\n Anexo \n\n \n\nhttp://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--\n\nLicense.html. \n\n \n\nIf you select the OnlineOpen option and your research is funded by The \n\nWellcome Trust and members of the Research Councils UK (RCUK) you will be \n\ngiven the opportunity to publish your article under a CC-BY license supporting \n\nyou in complying with Wellcome Trust and Research Councils UK requirements. \n\nFor more information on this policy and the Journal\u2019s compliant self-archiving \n\npolicy please visit: http://www.wiley.com/go/funderstatement. \n\n \n\nFor RCUK and Wellcome Trust authors click on the link below to preview the \n\nterms and conditions of this license: \n\n \n\nCreative Commons Attribution License OAA \n\n \n\nTo preview the terms and conditions of these open access agreements please \n\nvisit the Copyright FAQs hosted on Wiley Author Services \n\nhttp://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit \n\nhttp://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--\n\nLicense.html. \n\n2.8 OnlineOpen \n\nOnlineOpen is available to authors of primary research articles who wish to \n\nmake their article available to non-subscribers on publication, or whose funding \n\nagency requires grantees to archive the final version of their article. With \n\nOnlineOpen, the author, the author's funding agency, or the author's institution \n\npays a fee to ensure that the article is made available to non-subscribers upon \n\npublication via Wiley Online Library, as well as deposited in the funding \n\nagency's preferred archive. For the full list of terms and conditions, see \n\nhttp://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms \n\n \n\nAny authors wishing to send their paper OnlineOpen will be required to \n\ncomplete the payment form available from our website at: \n\nhttps://authorservices.wiley.com/bauthor/onlineopen_order.asp \n\n \n\n\n\n61 \n\n Anexo \n\n \n\nPrior to acceptance there is no requirement to inform an Editorial Office that you \n\nintend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen \n\narticles are treated in the same way as any other article. They go through the \n\njournal's standard peer-review process and will be accepted or rejected based \n\non their own merit. \n\n \n\n3. SUBMISSION OF MANUSCRIPTS \n\n \n\nManuscripts should be submitted electronically via the online submission site \n\nhttp://mc.manuscriptcentral.com/coir. The use of an online submission and peer \n\nreview site enables immediate distribution of manuscripts and consequentially \n\nspeeds up the review process. It also allows authors to track the status of their \n\nown manuscripts. Complete instructions for submitting a paper is available \n\nonline and below. Further assistance can be obtained from the Editorial \n\nAssistant Ms. Brigitte Baur. E-mail: coir@zmk.unibe.ch \n\n \n\n3.1. Getting Started \n\nLaunch your web browser (supported browsers include Internet Explorer 6 or \n\nhigher, Netscape 7.0, 7.1, or 7.2, Safari 1.2.4, or Firefox 1.0.4) and go to the \n\njournal's online Submission Site: http://mc.manuscriptcentral.com/coir \n\n \n\n\u2022 Log-in or click the 'Create Account' option if you are a first-time user. \n\n\u2022 If you are creating a new account. \n\n- After clicking on 'Create Account', enter your name and e-mail information and \n\nclick 'Next'. Your e-mail information is very important. \n\n- Enter your institution and address information as appropriate, and then click \n\n'Next.' \n\n- Enter a user ID and password of your choice (we recommend using your e-\n\nmail address as your user ID), and then select your area of expertise. Click \n\n'Finish'. \n\n\u2022 If you have an account, but have forgotten your log in details, go to Password \n\nHelp on the journals online submission system \n\nhttp://mc.manuscriptcentral.com/coir and enter your e-mail address. The system \n\nwill send you an automatic user ID and a new temporary password. \n\n\n\n62 \n\n Anexo \n\n \n\n\u2022  Log-in and select Corresponding Author Center. \n\n \n\n3.2. Submitting Your Manuscript \n\n\u2022 After you have logged in, click the 'Submit a Manuscript' link in the menu bar. \n\n\u2022 Enter data and answer questions as appropriate. You may copy and paste \n\ndirectly from your manuscript and you may upload your pre-prepared covering \n\nletter. \n\n\u2022 Click the 'Next' button on each screen to save your work and advance to the \n\nnext screen. \n\n\u2022 You are required to upload your files. \n\n- Click on the 'Browse' button and locate the file on your computer. \n\n- Select the designation of each file in the drop-down menu next to the Browse \n\nbutton. \n\n- When you have selected all files you wish to upload, click the 'Upload Files' \n\nbutton. \n\n\u2022 Review your submission (in HTML and PDF format) before sending to the \n\nJournal. Click the 'Submit' button when you are finished reviewing. \n\n \n\n3.3. Manuscript Files Accepted \n\nManuscripts should be uploaded as Word (.doc) or Rich Text Format (.rft) files \n\n(not write-protected) plus separate figure files. GIF, JPEG, PICT or Bitmap files \n\nare acceptable for submission, but only high-resolution TIF or EPS files are \n\nsuitable for printing. The files will be automatically converted to HTML and PDF \n\non upload and will be used for the review process. The text file must contain the \n\nentire manuscript including title page, abstract, text, references, tables, and \n\nfigure legends, but no embedded figures. In the text, please reference figures \n\nas for instance 'Figure 1', 'Figure 2' etc to match the tag name you choose for \n\nthe individual figure files uploaded. Manuscripts should be formatted as \n\ndescribed in the Author Guidelines below. \n\n \n\n3.4. Blinded Review \n\nAll manuscripts submitted to Clinical Oral Implants Research will be reviewed \n\nby two experts in the field. Clinical Oral Implants Research uses single blinded \n\n\n\n63 \n\n Anexo \n\n \n\nreview. The names of the reviewers will thus not be disclosed to the author \n\nsubmitting a paper. \n\n \n\n3.5. Suggest a Reviewer \n\nClinical Oral Implants Research attempts to keep the review process as short \n\nas possible to enable rapid publication of new scientific data. In order to \n\nfacilitate this process, please suggest the names and current email addresses \n\nof one potential international reviewer whom you consider capable of reviewing \n\nyour manuscript. In addition to your choice the journal editor will choose one or \n\ntwo reviewers as well. \n\n \n\n3.6. Suspension of Submission Mid-way in the Submission Process \n\nYou may suspend a submission at any phase before clicking the 'Submit' button \n\nand save it to submit later. The manuscript can then be located under \n\n'Unsubmitted Manuscripts' and you can click on 'Continue Submission' to \n\ncontinue your submission when you choose to. \n\n \n\n3.7. E-mail Confirmation of Submission \n\nAfter submission you will receive an e-mail to confirm receipt of your \n\nmanuscript. If you do not receive the confirmation email after 24 hours, please \n\ncheck your e-mail address carefully in the system. If the e-mail address is \n\ncorrect please contact your IT department. The error may be caused by some \n\nsort of spam filtering on your e-mail server. Also, the e-mails should be received \n\nif the IT department adds our email server (uranus.scholarone.com) to their \n\nwhitelist. \n\n \n\n3.8. Manuscript Status \n\nYou can access ScholarOne Manuscripts (formerly known as Manuscript \n\nCentral) any time to check your 'Author Centre' for the status of your \n\nmanuscript. The Journal will inform you by e-mail once a decision has been \n\nmade. \n\n \n\n3.9. Submission of Revised Manuscripts \n\n\n\n64 \n\n Anexo \n\n \n\nTo submit your revised manuscript, locate your manuscript under 'Manuscripts \n\nwith Decisions' and click on 'Submit a Revision' . Please remember to delete \n\nany old files uploaded when you upload your revised manuscript. \n\n \n\n4. MANUSCRIPT TYPES ACCEPTED \n\nOriginal research articles of high scientific merit in the field of material sciences, \n\nphysiology of wound healing, biology of tissue integration of implants, diagnosis \n\nand treatment planning, prevention of pathologic processes jeopardizing the \n\nlongevity of implants, clinical trials on implant systems, stomatognathic \n\nphysiology related to oral implants, new developments in therapeutic concepts \n\nand prosthetic rehabilitation. \n\n \n\nReview articles by experts on new developments in basic sciences related to \n\nimplant dentistry and clinically applied concepts. Reviews are generally by \n\ninvitation only and have to be approved by the Editor-in-Chief before \n\nsubmission. \n\n \n\nCase reports and case series, but only if they provide or document new \n\nfundamental knowledge and if they use language understandable to the \n\nclinician. \n\n \n\nNovel developments if they provide a technical novelty for any implant system. \n\n \n\nShort communications of important research findings in a concise format and for \n\nrapid publication. \n\n \n\nTreatment rational by experts with evidence-based treatment approach. \n\n \n\nProceedings of international meetings may also be considered for publication at \n\nthe discretion of the Editor. \n\n \n\n5. MANUSCRIPT FORMAT AND STRUCTURE \n\n \n\n\n\n65 \n\n Anexo \n\n \n\n5.1. Page Charge \n\nArticles exceeding 10 published pages are subject to a charge of USD 160 per \n\nadditional page. One published page amounts approximately to 5,500 \n\ncharacters (excluding figures and tables). \n\n \n\n5.2. Format \n\n \n\nLanguage: The language of publication is English. Authors for whom English is \n\na second language might choose to have their manuscript professionally edited \n\nby an English speaking person before submission to make sure the English is \n\nof high quality. A list of independent suppliers of editing services can be found \n\nat http://authorservices.wiley.com/bauthor/english_language.asp. All services \n\nare paid for and arranged by the author, and use of one of these services does \n\nnot guarantee acceptance or preference for publication \n\n \n\nAbbreviations, Symbols and Nomenclature: The symbol % is to be used for \n\npercent, h for hour, min for minute, and s for second. In vitro, in vivo, in situ and \n\nother Latin expressions are to be italicised. Use only standard abbreviations. All \n\nunits will be metric. Use no roman numerals in the text. In decimals, a decimal \n\npoint and not a comma will be used. Avoid abbreviations in the title. The full \n\nterm for which an abbreviation stands should precede its first use in the text \n\nunless it is a standard unit of measurement. In cases of doubt, the spelling \n\northodoxy of Webster's third new international dictionary will be adhered to. \n\n \n\nScientific Names: Proper names of bacteria should be binomial and should be \n\nsingly underlined on the typescript. The full proper name (e.g., Streptococcus \n\nsanguis) must be given upon first mention. The generic name may be \n\nabbreviated thereafter with the first letter of the genus (e.g., S. sanguis). If \n\nabbreviation of the generic name could cause confusion, the full name should \n\nbe used. If the vernacular form of a genus name (e.g., streptococci) is used, the \n\nfirst letter of the vernacular name is not capitalised and the name is not \n\nunderlined. Use of two letters of the genus (e.g., Ps. for Peptostreptococcus) is \n\nincorrect, even though it might avoid ambiguity. With regard to drugs, generic \n\nnames should be used instead of proprietary names. If a proprietary name is \n\nused, it must be attached when the term is first used. \n\n\n\n66 \n\n Anexo \n\n \n\n \n\n5.2. Structure \n\nAll manuscripts submitted to Clinical Oral Implants Research should include \n\nTitle Page, Abstract, Main Text and Acknowledgements, Tables, Figures and \n\nFigure Legends as appropriate. \n\n \n\nTitle Page: should contain the title of the article, full name(s) of the authors (no \n\nmore than 6) and institutional affiliation(s), a running title not exceeding 60 \n\nletters and spaces, and the name, telephone and fax numbers, email and \n\ncomplete mailing address of the author responsible for correspondence. The \n\nauthor must list appropriate key words for indexing purposes. \n\n \n\nAbstract: should not to exceed 250 words. This should be structured into: \n\nobjectives, material and methods, results, conclusions, and no other \n\ninformation. \n\n \n\nMain Text of Original Research Article should include Introduction, Material and \n\nMethods, Results and Discussion.  \n\n \n\nIntroduction: Summarise the rationale and purpose of the study, giving only \n\nstrictly pertinent references. Do not review existing literature extensively. State \n\nclearly the working hypothesis. \n\n \n\nMaterial and Methods: Material and methods should be presented in sufficient \n\ndetail to allow confirmation of the observations. Published methods should be \n\nreferenced and discussed only briefly, unless modifications have been made. \n\nIndicate the statistical methods used, if applicable. \n\n \n\nResults: Present your results in a logical sequence in the text, tables, and \n\nillustrations. Do not repeat in the text all data in the tables and illustrations. The \n\nimportant observations should be emphasised. \n\n \n\nDiscussion: Summarise the findings without repeating in detail the data given in \n\nthe Results section. Relate your observations to other relevant studies and \n\n\n\n67 \n\n Anexo \n\n \n\npoint out the implications of the findings and their limitations. Cite other relevant \n\nstudies. \n\n \n\nMain Text of Short Communications: Short communications are limited to two \n\nprinted pages including illustrations and references and need not follow the \n\nusual division into material and methods, etc., but should have an abstract. \n\n \n\nAcknowledgements: Acknowledge only persons who have made substantive \n\ncontributions to the study. Authors are responsible for obtaining written \n\npermission from everyone acknowledged by name because readers may infer \n\ntheir endorsement of the data and conclusions. Sources of financial support \n\nshould be acknowledged. \n\n \n\n5.3. References \n\nReferences should quote the last name(s) of the author(s) and the year of \n\npublication (Black &amp; Miller 1988). Three or more authors should always be \n\nreferred to as, for example, (Fox et al. 1977). \n\nA list of references should be given at the end of the paper and should follow \n\nthe recommendations in Units, symbols and abbreviations: a guide for biological \n\nand medical editors and authors (1988), p. 52, London: The Royal Society of \n\nMedicine. \n\n \n\na) The arrangement of the references should be alphabetical by author's \n\nsurname. \n\n \n\nb) The order of the items in each reference should be: \n\n(i) for journal references: \n\nname(s) of author(s), year, title of paper, title of journal, volume number, first \n\nand last page numbers. \n\n(ii) for book references: \n\nname(s) of author(s), year, title of book, edition, volume, chapter and/ or page \n\nnumber, town of publication, publisher. \n\n \n\n\n\n68 \n\n Anexo \n\n \n\nc) Author's names should be arranged thus: Daniels, J.A., Kelly, R.A. &amp; Til, T.C. \n\nNote the use of the ampersand and omission of comma before it. Author's \n\nnames when repeated in the next reference are always spelled out in full. \n\n \n\nd) The year of publication should be surrounded by parentheses: (1966). \n\n \n\nc) The title of the paper should be included, without quotation marks. \n\n \n\nf) The journal title should be written in full, italicised, and followed by volume \n\nnumber in bold type, and page numbers. \n\nExamples: \n\nTonetti, M. S., Schmid, J., H\u00e4mmerle,C. H. &amp; Lang, N. P. (1993) Intraepithelial \n\nantigen-presenting cells in the keratinized mucosa around teeth and \n\nosseointegrated implants. Clinical Oral Implants Research 4: 177-186. \n\nPoole, B., Ohkuma, S. &amp; Warburton, M. (1978) Some aspects of the intracellular \n\nbreakdown of erogenous and endogenous proteins. In: Segal, H.S. &amp; Doyle, \n\nD.J., eds. Protein turnover and lysosome function, 1st edition, p. 43. New York: \n\nAcademic Press. \n\n \n\nWe recommend the use of a tool such as Reference Manager for reference \n\nmanagement and formatting. Reference Manager reference styles can be \n\nsearched for here: www.refman.com/support/rmstyles.asp \n\n \n\n5.4. Tables, Figures and Figure Legends \n\n \n\nTables: Tables should be numbered consecutively with Arabic numerals. Type \n\neach table on a separate sheet, with titles making them self-explanatory. Due \n\nregard should be given to the proportions of the printed page. \n\n \n\nFigures: All figures should clarify the text and their number should be kept to a \n\nminimum. Details must be large enough to retain their clarity after reduction in \n\nsize. Illustrations should preferably fill a single-column width (81 mm) after \n\nreduction, although in exceptional cases 120mm (double-column) and 168 mm \n\n\n\n69 \n\n Anexo \n\n \n\n(full page) widths will be accepted. Micrographs should be designed to be \n\nreproduced without reduction, and they should be dressed directly on the \n\nmicrograph with a linear size scale, arrows, and other designators as needed. \n\nEach figure should have a legend \n\n \n\nPreparation of Electronic Figures for Publication: Although low quality images \n\nare adequate for review purposes, print publication requires high quality images \n\nto prevent the final product being blurred or fuzzy. Submit EPS (lineart) or TIFF \n\n(halftone/photographs) files only. MS PowerPoint and Word Graphics are \n\nunsuitable for printed pictures. Do not use pixel-oriented programmes. Scans \n\n(TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi \n\n(line drawings) in relation to the reproduction size (see below). EPS files should \n\nbe saved with fonts embedded (and with a TIFF preview if possible). For \n\nscanned images, the scanning resolution (at final image size) should be as \n\nfollows to ensure good reproduction: lineart:  >600 dpi; half-tones (including gel \n\nphotographs): >300 dpi; figures containing both halftone and line images: >600 \n\ndpi. \n\n \n\nFurther information can be obtained at Wiley-Blackwell\u2019s guidelines for figures: \n\nhttp://authorservices.wiley.com/bauthor/illustration.asp \n\n \n\nCheck your electronic artwork before submitting it: \n\nhttp://authorservices.wiley.com/bauthor/eachecklist.asp \n\n \n\nPermissions: If all or parts of previously published illustrations are used, \n\npermission must be obtained from the copyright holder concerned. It is the \n\nauthor's responsibility to obtain these in writing and provide copies to the \n\nPublishers. \n\n \n\n6. AFTER ACCEPTANCE \n\nUpon acceptance of a paper for publication, the manuscript will be forwarded to \n\nthe Production Editor who is responsible for the production of the journal. \n\n \n\n6.1 Proof Corrections \n\n\n\n70 \n\n Anexo \n\n \n\nThe corresponding author will receive an email alert containing a link to a web \n\nsite.  A working email address must therefore be provided for the corresponding \n\nauthor.  The proof can be downloaded as a PDF (portable document format) file \n\nfrom this site. Acrobat Reader will be required in order to read this file. This \n\nsoftware can be downloaded (free of charge) from the following Web site: \n\nwww.adobe.com/products/acrobat/readstep2.html. This will enable the file to be \n\nopened, read on screen, and printed out in order for any corrections to be \n\nadded. Further instructions will be sent with the proof. Hard copy proofs will be \n\nposted if no e-mail address is available; in your absence, please arrange for a \n\ncolleague to access your e-mail to retrieve the proofs. Proofs must be returned \n\nto the Production Editor within three days of receipt. \n\n \n\nExcessive changes made by the author in the proofs, excluding typesetting \n\nerrors, will be charged separately. Other than in exceptional circumstances, all \n\nillustrations are retained by the publisher. Please note that the author is \n\nresponsible for all statements made in his work, including changes made by the \n\ncopy editor. \n\n \n\nArticles should not normally exceed 10 printed pages, including illustrations and \n\nreferences. Additional pages will be charged to the author(s) at the rate of USD \n\n160 per page. \n\n \n\n6.2 Early View (Publication Prior to Print) \n\nClinical Oral Implants Research is covered by Wiley-Blackwell's Early View \n\nservice. Early View articles are complete full-text articles published online in \n\nadvance of their publication in a printed issue. Early View articles are complete \n\nand final. They have been fully reviewed, revised and edited for publication, and \n\nthe authors' final corrections have been incorporated. Because they are in final \n\nform, no changes can be made after online publication. The nature of Early \n\nView articles means that they do not yet have volume, issue or page numbers, \n\nso Early View articles cannot be cited in the traditional way. They are therefore \n\ngiven a Digital Object Identifier (DOI), which allows the article to be cited and \n\ntracked before it is allocated to an issue. After print publication, the DOI remains \n\nvalid and can continue to be used to cite and access the article. \n\n \n\n\n\n71 \n\n Anexo \n\n \n\n6.3 Author Services \n\nOnline production tracking is available for your article through Wiley-Blackwell's \n\nAuthor Services. Author Services enables authors to track their article - once it \n\nhas been accepted - through the production process to publication online and in \n\nprint. Authors can check the status of their articles online and choose to receive \n\nautomated e-mails at key stages of production. The author will receive an e-mail \n\nwith a unique link that enables them to register and have their article \n\nautomatically added to the system. Please ensure that a complete e-mail \n\naddress is provided when submitting the manuscript. Visit \n\nhttp://authorservices.wiley.com/bauthor/ for more details on online production \n\ntracking and for a wealth of resources including."}]}}}